Queens University Belfast – Confidence in Concept 2019
Lead Research Organisation:
Queen's University Belfast
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Organisations
People |
ORCID iD |
Alan Stitt (Principal Investigator) |
Publications
Creane S
(2023)
In vitro evaluation of the potential use of snake-derived peptides in the treatment of respiratory infections using inhalation therapy: A proof of concept study
in European Journal of Pharmaceutical Sciences
McKelvey MC
(2022)
Cathepsin S Contributes to Lung Inflammation in Acute Respiratory Distress Syndrome.
in American journal of respiratory and critical care medicine
Quinn GP
(2022)
classifieR a flexible interactive cloud-application for functional annotation of cancer transcriptomes.
in BMC bioinformatics
Cornelius V
(2021)
Diabetic endotheliopathy: RNA-binding proteins as new therapeutic targets
in The International Journal of Biochemistry & Cell Biology
Cornelius VA
(2021)
Alternative Splicing: A Key Mediator of Diabetic Vasculopathy.
in Genes
Yang C
(2020)
Targeting QKI-7 in vivo restores endothelial cell function in diabetes.
in Nature communications
Todd GM
(2020)
Secreted BMP antagonists and their role in cancer and bone metastases.
in Bone
Description | Opportunity-Led Professor Ultan Power - Repurposing FDA-approved drugs for treatment of 2019-nCoV-induced disease |
Amount | £208,070 (GBP) |
Funding ID | COM/5613/20 |
Organisation | Public Health Agency (PHA) |
Sector | Public |
Country | United Kingdom |
Start | 10/2020 |
End | 09/2021 |
Description | Repurposing approved drugs as potent antiviral combinations to treat COVID-19 disease. |
Amount | £640,433 (GBP) |
Funding ID | MRC - BMC DPFS - MR/W021641/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2022 |
End | 12/2024 |
Description | Targeting Deubiquitinases to Treat Drug-Resistant Colorectal Cancer |
Amount | £225,656 (GBP) |
Funding ID | 56232 |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start | 02/2021 |
End | 12/2023 |